Comparison of KRAS Mutation Assessment in Tumor DNA and Circulating Free DNA in Plasma and Serum Samples
暂无分享,去创建一个
Emma Donald | L. Kam-Morgan | M. Eisenberg | S. Morgan | Shethah R. Morgan | Jessica Whiteley | John Smith | Marcia T. Eisenberg | Eddie Kallam | Lauren Kam-Morgan | J. Whiteley | E. Donald | John C Smith | E. Kallam
[1] S. Jewell,et al. Copyright © American Society for Investigative Pathology Review Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids , 2022 .
[2] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] E. Urgell,et al. Agreement between K-ras sequence variations detected in plasma and tissue DNA in pancreatic and colorectal cancer. , 2006, Clinical chemistry.
[4] E. Van Cutsem,et al. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] T. Frebourg,et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.
[6] P. Quirke,et al. Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing , 2011, Analytical cellular pathology.
[7] E. Van Cutsem,et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] F. A. Benko,et al. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. , 2000, Journal of the National Cancer Institute.
[9] P. Laurent-Puig,et al. Circulating free tumor DNA and colorectal cancer. , 2010, Gastroenterologie clinique et biologique.
[10] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[11] J. Hunt,et al. KRAS Mutation Testing in Colorectal Cancer , 2009, Advances in anatomic pathology.
[12] P. Spellman,et al. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays , 2009, BMC Medical Genomics.
[13] M. Somerfield,et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. Jares,et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program , 2008, Virchows Archiv.
[15] Manuel Hidalgo,et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Klaus Pantel,et al. Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.
[17] Josep Tabernero,et al. EGFR and KRAS in colorectal cancer. , 2010, Advances in clinical chemistry.
[18] M. Fleischhacker,et al. Cell-free DNA resuscitated for tumor testing , 2008, Nature Medicine.
[19] S. Goodman,et al. Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.
[20] I. Nagtegaal,et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients , 2011, British Journal of Cancer.
[21] A. Lièvre,et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Bruno Landi,et al. Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis , 2002, International journal of cancer.